EUKARYOTIC TRANSLATION INITIATION FACTORS (EIFs) AS NOVEL BIOMARKERS IN PANCREATIC CANCER

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention identifies specific eukaryotic translation initiation factors (eIF1, eIF2a, eIF3C, eIF6) as novel biomarkers for pancreatic cancer. By measuring the levels of these factors in biological samples (like blood or tissue), the methods enable not only the diagnosis of pancreatic cancer but also grading its severity (low-grade vs. high-grade) and predicting patient survival, especially using eIF1 as a prognostic marker. The patent also provides kits for these diagnostic purposes, potentially allowing for easier clinical implementation.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of pancreatic cancer in suspected patients.
• Distinguishing between low-grade and high-grade pancreatic cancer to guide therapy decisions.
• Providing prognostic information to patients and clinicians to assist in treatment planning.
• Monitoring changes in biomarker levels to assess response to therapy or disease progression.
• Integration with point-of-care test kits or laboratory diagnostics for routine cancer screening and monitoring.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables earlier and more accurate detection of pancreatic cancer compared to existing methods.
• Provides objective grading and prognosis based on biomarker levels rather than solely on imaging or histology.
• Potential for non-invasive testing using blood or other body fluids.
• Useful for both initial diagnosis and ongoing monitoring of disease status or response to treatment.
• Facilitates personalized treatment planning and improves patient stratification for therapeutic decisions.
• Kits can be adapted for rapid and efficient point-of-care testing in clinical settings.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a method of diagnosing pancreatic cancer in an individual. Further, the present invention relates to a method of grading pancreatic cancer in an individual. Furthermore, the present invention relates to a method of differentiating between low-grade pancreatic cancer and high-grade pancreatic cancer in an individual. In addition, the present invention relates to a method for providing a survival prognosis to an individual suffering from pancreatic cancer. Moreover, the present invention relates to kits for performing the above-mentioned methods.